International Journal of Pharmaceutical Compounding

Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists

Author(s): Paoletti James E, Benavides Tomas J

Issue: Nov/Dec 1998 - Environmental Compounds

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 1998 Pg. 414-415	Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists Author(s): Paoletti James E, Benavides Tomas J
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2020 Pg. 519-527	Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Author(s): Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott
Jul/Aug 2003 Pg. 281-285	Containment of Hazardous Particulates in the Compounding Pharmacy Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 356	PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800> Author(s): Allen Loyd V Jr
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D
Sep/Oct 2001 Pg. 362-364	Minimizing the Risk of Cholesterol-Lowering Therapy Author(s): Pratt Sam
May/Jun 2005 Pg. 201-205	Combating Cardiovascular Disease with Compounded Medications -- Part 2: Clinical and Compounding Issues for Antihypertensive Drugs Author(s): Harrington Catherine A, Cauffield Jacintha
Nov/Dec 2015 Pg. 514-520	Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States Author(s): Lobb William B, Wilkin Noel E, Holmes Erin R
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Jul/Aug 2010 Pg. 310-314	Unique Challenges in Compounding: Managing Severe Musculoskeletal Pain in a Recovered Substance Abuser Author(s): Christiansen Joel, White Lyndell
May/Jun 2010 Pg. 182-192	Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jul/Aug 2013 Pg. 339-343	Patient-centered Care as Value-added Service by Compounding Pharmacists Author(s): McPherson Timothy B, Fontane Patrick E, Day Jonathan R
Nov/Dec 2021 Pg. 515-522	Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding Author(s): Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
Jan/Feb 2022 Pg. 72-79	Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding (Reprint) Author(s): Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
Jan/Feb 2014 Pg. 30-34	Determination of Risk for Sterile Preparations Author(s): Freedman ben-Horin Shimon, Rousso Tamaro
Mar/Apr 2016 Pg. 95-96	Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations Author(s): McCrory Gary
Jul/Aug 2003 Pg. 258-263	Patient Satisfaction with Pharmacist Intervention and Consultation in HRT Author(s): DiMaggio Jennifer Lyn, Reed-Kane Dana
Jan/Feb 2002 Pg. 8-10	Compounding with Controlled Substances Author(s): Whalen Mary Kate
Jan/Feb 2014 Pg. 6-12	The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013 Author(s): Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc

Abstract

Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists

Page(s): 414-415

Abstract

Related Keywords

Related Categories

Related Articles from IJPC